What is B. Riley’s Estimate for Agenus FY2025 Earnings?

Agenus Inc. (NASDAQ:AGEN) – Equities research analysts at B. Riley boosted their FY2025 earnings per share estimates for shares of Agenus in a report released on Thursday, May 15th. B. Riley analyst M. Mamtani now anticipates that the biotechnology company will post earnings per share of $6.14 for the year, up from their prior estimate of ($3.44). B. Riley has a “Buy” rating on the stock. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. B. Riley also issued estimates for Agenus’ FY2026 earnings at ($4.88) EPS.

AGEN has been the topic of a number of other research reports. HC Wainwright restated a “neutral” rating on shares of Agenus in a research note on Tuesday, May 13th. StockNews.com upgraded shares of Agenus from a “sell” rating to a “hold” rating in a research note on Friday, March 21st. Finally, Robert W. Baird upped their target price on shares of Agenus from $3.00 to $4.00 and gave the stock a “neutral” rating in a report on Tuesday, May 13th. Six research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, Agenus has an average rating of “Hold” and a consensus price target of $9.00.

Agenus Stock Up 1.3%

AGEN stock opened at $3.84 on Monday. The business’s 50-day moving average price is $2.32 and its 200-day moving average price is $2.89. The stock has a market cap of $105.28 million, a P/E ratio of -0.34 and a beta of 1.48. Agenus has a twelve month low of $1.38 and a twelve month high of $19.69.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.03) EPS for the quarter, topping analysts’ consensus estimates of ($1.61) by $0.58. The company had revenue of $24.07 million during the quarter, compared to analysts’ expectations of $26.38 million.

Institutional Investors Weigh In On Agenus

Several institutional investors and hedge funds have recently modified their holdings of AGEN. B. Riley Financial Inc. purchased a new position in Agenus during the fourth quarter valued at $2,074,000. Siren L.L.C. bought a new position in shares of Agenus during the 1st quarter valued at about $752,000. AQR Capital Management LLC grew its position in shares of Agenus by 3,080.3% during the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after purchasing an additional 427,604 shares in the last quarter. Gilead Sciences Inc. purchased a new position in shares of Agenus during the fourth quarter valued at about $635,000. Finally, Invesco Ltd. bought a new stake in shares of Agenus in the first quarter worth about $88,000. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.